Market capitalization | $40.40m |
Enterprise Value | $-52.36m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.80 |
EV/Sales (TTM) EV/Sales | -0.60 |
P/S ratio (TTM) P/S ratio | 0.46 |
P/B ratio (TTM) P/B ratio | 0.95 |
Revenue growth (TTM) Revenue growth | 88.35% |
Revenue (TTM) Revenue | $87.64m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
5 Analysts have issued a Precision BioSciences, Inc. forecast:
5 Analysts have issued a Precision BioSciences, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 88 88 |
88%
88%
|
|
Gross Profit | 81 81 |
118%
118%
|
|
EBITDA | -0.89 -0.89 |
99%
99%
|
EBIT (Operating Income) EBIT | -7.29 -7.29 |
91%
91%
|
Net Profit | 8.52 8.52 |
110%
110%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.
Head office | United States |
CEO | Michael Amoroso |
Employees | 109 |
Founded | 2006 |
Website | www.precisionbiosciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.